Cellular Biomedicine Inc logo

CBMG - Cellular Biomedicine Inc Share Price

$18.4 -0.0  -0.1%

Last Trade - 21/10/20

Sector
Healthcare
Size
Small Cap
Market Cap £276.5m
Enterprise Value £281.1m
Revenue £225k
Position in Universe 3276th / 6436
Bullish
Bearish
Unlock CBMG Revenue
Momentum
Relative Strength (%)
1m -5.69%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.54%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.56 2.51 0.63 0.34 0.22 0.34 2.00 4.00 -9.6%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Cellular Biomedicine Group Inc revenues decreased from $49K to $0K. Net loss increased 17% to $25.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 21% to $17M (expense), Interest expense, Net increase from $158K to $431K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CBMG Revenue Unlock CBMG Revenue

Net Income

CBMG Net Income Unlock CBMG Revenue

Normalised EPS

CBMG Normalised EPS Unlock CBMG Revenue

PE Ratio Range

CBMG PE Ratio Range Unlock CBMG Revenue

Dividend Yield Range

CBMG Dividend Yield Range Unlock CBMG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CBMG EPS Forecasts Unlock CBMG Revenue
Profile Summary

Cellular Biomedicine Group, Inc. (CBMG), is a clinical-stage biopharmaceutical company. The Company is leveraging its cell-based technologies to develop immunotherapies for the treatment of cancer and stem cell therapies for the treatment of degenerative diseases. The Company provides comprehensive and integrated research and manufacturing services throughout the discovery, development and manufacturing spectrum for cell-based technologies. The Company’s primary focus has been to serve the growing health care market initially in China by marketing and commercializing immune cell and stem cell therapeutics, related tools and products. The Company’s treatment focal points are cancer and Knee Osteoarthritis (KOA). It is focusing its clinical development efforts on assets such as C-CAR088, C-CAR039, TIL051, AFT-TCRT in China and/or United States. It has also completed a Phase-I/IIa clinical study, in China, for our KOA therapy named ReJoin.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated January 18, 2013
Public Since June 18, 2014
No. of Shareholders: 1,700
No. of Employees: 217
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 19,432,979
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CBMG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CBMG
Upcoming Events for CBMG
Frequently Asked Questions for Cellular Biomedicine Inc
What is the Cellular Biomedicine Inc share price?

As of 21/10/20, shares in Cellular Biomedicine Inc are trading at $18.4, giving the company a market capitalisation of £276.5m. This share price information is delayed by 15 minutes.

How has the Cellular Biomedicine Inc share price performed this year?

Shares in Cellular Biomedicine Inc are currently trading at $18.4 and the price has moved by 24.8% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cellular Biomedicine Inc price has moved by 9.1% over the past year.

What are the analyst and broker recommendations for Cellular Biomedicine Inc?

Of the analysts with advisory recommendations for Cellular Biomedicine Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cellular Biomedicine Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Cellular Biomedicine Inc next release its financial results?

Cellular Biomedicine Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Cellular Biomedicine Inc dividend yield?

Cellular Biomedicine Inc does not currently pay a dividend.

Does Cellular Biomedicine Inc pay a dividend?

Cellular Biomedicine Inc does not currently pay a dividend.

When does Cellular Biomedicine Inc next pay dividends?

Cellular Biomedicine Inc does not currently pay a dividend.

How do I buy Cellular Biomedicine Inc shares?

To buy shares in Cellular Biomedicine Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cellular Biomedicine Inc?

Shares in Cellular Biomedicine Inc are currently trading at $18.4, giving the company a market capitalisation of £276.5m.

Where are Cellular Biomedicine Inc shares listed? Where are Cellular Biomedicine Inc shares listed?

Here are the trading details for Cellular Biomedicine Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: CBMG
What kind of share is Cellular Biomedicine Inc?

Based on an overall assessment of its quality, value and momentum, Cellular Biomedicine Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cellular Biomedicine Inc share price forecast 2020?

Shares in Cellular Biomedicine Inc are currently priced at $18.4. At that level they are trading at 3.15% discount to the analyst consensus target price of 0.00.

Analysts covering Cellular Biomedicine Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.8 for the next financial year.

How can I tell whether the Cellular Biomedicine Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cellular Biomedicine Inc. Over the past six months, the relative strength of its shares against the market has been 5.23%. At the current price of $18.4, shares in Cellular Biomedicine Inc are trading at 15.56% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cellular Biomedicine Inc PE Ratio?

We were not able to find PE ratio data for Cellular Biomedicine Inc.

Who are the key directors of Cellular Biomedicine Inc?

Cellular Biomedicine Inc's management team is headed by:

Wen Liu - IND
Andrew Chan - SVP
Bizuo Liu - CEO
Chun Kwok Alan Au - IND
Terry Belmont - CHM
Yihong Yao - CSO
Hansheng Zhou - IND
Gang Ji - IND
Darren O'Brien - IND
Who are the major shareholders of Cellular Biomedicine Inc?

Here are the top five shareholders of Cellular Biomedicine Inc based on the size of their shareholding:

Dangdai International Group Co., Ltd. Corporation
Percentage owned: 11.68% (2.27m shares)
Sailing Capital Advisors (HK) Ltd. Private Equity
Percentage owned: 8.81% (1.71m shares)
Novartis Pharma AG Corporation
Percentage owned: 7.5% (1.46m shares)
Maplebrook Ltd Corporation
Percentage owned: 5.69% (1.10m shares)
Mission Right, Ltd. Corporation
Percentage owned: 5.33% (1.04m shares)
Similar to CBMG
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.